AXON vs. RGEN: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at AXON and RGEN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | AXON | RGEN |
|---|---|---|
| Company Name | Axon Enterprise, Inc. | Repligen Corporation |
| Country | United States | United States |
| GICS Sector | Industrials | Health Care |
| GICS Industry | Aerospace & Defense | Life Sciences Tools & Services |
| Market Capitalization | 60.42 billion USD | 6.69 billion USD |
| Exchange | NasdaqGS | NasdaqGS |
| Listing Date | June 19, 2001 | April 29, 1986 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of AXON and RGEN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | AXON | RGEN |
|---|---|---|
| 5-Day Price Return | 0.81% | -0.64% |
| 13-Week Price Return | 3.16% | -2.99% |
| 26-Week Price Return | 49.97% | -25.23% |
| 52-Week Price Return | 113.51% | -18.94% |
| Month-to-Date Return | 1.88% | 1.55% |
| Year-to-Date Return | 29.51% | -17.41% |
| 10-Day Avg. Volume | 0.48M | 0.62M |
| 3-Month Avg. Volume | 0.62M | 0.81M |
| 3-Month Volatility | 49.69% | 43.83% |
| Beta | 1.46 | 1.10 |
Profitability
Return on Equity (TTM)
AXON
13.43%
Aerospace & Defense Industry
- Max
- 43.89%
- Q3
- 22.42%
- Median
- 12.50%
- Q1
- 5.21%
- Min
- -6.24%
AXON’s Return on Equity of 13.43% is on par with the norm for the Aerospace & Defense industry, indicating its profitability relative to shareholder equity is typical for the sector.
RGEN
-0.69%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.55%
- Median
- 6.22%
- Q1
- 3.86%
- Min
- -6.95%
RGEN has a negative Return on Equity of -0.69%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
AXON
13.64%
Aerospace & Defense Industry
- Max
- 14.54%
- Q3
- 8.08%
- Median
- 6.17%
- Q1
- 2.49%
- Min
- -1.63%
A Net Profit Margin of 13.64% places AXON in the upper quartile for the Aerospace & Defense industry, signifying strong profitability and more effective cost management than most of its peers.
RGEN
-2.05%
Life Sciences Tools & Services Industry
- Max
- 27.28%
- Q3
- 16.17%
- Median
- 7.24%
- Q1
- 3.00%
- Min
- -3.05%
RGEN has a negative Net Profit Margin of -2.05%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
AXON
-1.26%
Aerospace & Defense Industry
- Max
- 16.63%
- Q3
- 10.38%
- Median
- 8.29%
- Q1
- 6.21%
- Min
- 0.95%
AXON has a negative Operating Profit Margin of -1.26%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
RGEN
-3.51%
Life Sciences Tools & Services Industry
- Max
- 33.15%
- Q3
- 19.34%
- Median
- 13.02%
- Q1
- 8.05%
- Min
- -4.38%
RGEN has a negative Operating Profit Margin of -3.51%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | AXON | RGEN |
|---|---|---|
| Return on Equity (TTM) | 13.43% | -0.69% |
| Return on Assets (TTM) | 6.28% | -0.48% |
| Net Profit Margin (TTM) | 13.64% | -2.05% |
| Operating Profit Margin (TTM) | -1.26% | -3.51% |
| Gross Profit Margin (TTM) | 60.47% | 50.99% |
Financial Strength
Current Ratio (MRQ)
AXON
2.95
Aerospace & Defense Industry
- Max
- 3.09
- Q3
- 1.98
- Median
- 1.23
- Q1
- 1.03
- Min
- 0.02
AXON’s Current Ratio of 2.95 is in the upper quartile for the Aerospace & Defense industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
RGEN
8.59
Life Sciences Tools & Services Industry
- Max
- 4.76
- Q3
- 2.77
- Median
- 1.85
- Q1
- 1.40
- Min
- 0.43
RGEN’s Current Ratio of 8.59 is exceptionally high, placing it well outside the typical range for the Life Sciences Tools & Services industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.
Debt-to-Equity Ratio (MRQ)
AXON
0.73
Aerospace & Defense Industry
- Max
- 1.70
- Q3
- 1.04
- Median
- 0.68
- Q1
- 0.41
- Min
- 0.00
AXON’s Debt-to-Equity Ratio of 0.73 is typical for the Aerospace & Defense industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
RGEN
0.26
Life Sciences Tools & Services Industry
- Max
- 1.75
- Q3
- 0.83
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
RGEN’s Debt-to-Equity Ratio of 0.26 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
AXON
888.35
Aerospace & Defense Industry
- Max
- 36.57
- Q3
- 19.90
- Median
- 7.04
- Q1
- 2.40
- Min
- -7.63
With an Interest Coverage Ratio of 888.35, AXON demonstrates a superior capacity to service its debt, placing it well above the typical range for the Aerospace & Defense industry. This stems from either robust earnings or a conservative debt load.
RGEN
13.28
Life Sciences Tools & Services Industry
- Max
- 29.61
- Q3
- 23.24
- Median
- 6.07
- Q1
- 2.18
- Min
- -14.08
RGEN’s Interest Coverage Ratio of 13.28 is positioned comfortably within the norm for the Life Sciences Tools & Services industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | AXON | RGEN |
|---|---|---|
| Current Ratio (MRQ) | 2.95 | 8.59 |
| Quick Ratio (MRQ) | 2.56 | 7.04 |
| Debt-to-Equity Ratio (MRQ) | 0.73 | 0.26 |
| Interest Coverage Ratio (TTM) | 888.35 | 13.28 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
AXON
0.00%
Aerospace & Defense Industry
- Max
- 2.03%
- Q3
- 1.22%
- Median
- 0.43%
- Q1
- 0.00%
- Min
- 0.00%
AXON currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
RGEN
0.00%
Life Sciences Tools & Services Industry
- Max
- 1.80%
- Q3
- 0.78%
- Median
- 0.37%
- Q1
- 0.00%
- Min
- 0.00%
RGEN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
AXON
0.00%
Aerospace & Defense Industry
- Max
- 83.87%
- Q3
- 49.90%
- Median
- 16.48%
- Q1
- 0.00%
- Min
- 0.00%
AXON has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
RGEN
0.00%
Life Sciences Tools & Services Industry
- Max
- 156.00%
- Q3
- 65.73%
- Median
- 23.81%
- Q1
- 0.00%
- Min
- 0.00%
RGEN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | AXON | RGEN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
AXON
183.06
Aerospace & Defense Industry
- Max
- 65.97
- Q3
- 54.11
- Median
- 34.53
- Q1
- 23.66
- Min
- 0.00
At 183.06, AXON’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Aerospace & Defense industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
RGEN
--
Life Sciences Tools & Services Industry
- Max
- 117.96
- Q3
- 65.59
- Median
- 37.26
- Q1
- 27.51
- Min
- 1.73
P/E Ratio data for RGEN is currently unavailable.
Price-to-Sales Ratio (TTM)
AXON
24.98
Aerospace & Defense Industry
- Max
- 8.07
- Q3
- 4.49
- Median
- 2.42
- Q1
- 1.39
- Min
- 0.00
With a P/S Ratio of 24.98, AXON trades at a valuation that eclipses even the highest in the Aerospace & Defense industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
RGEN
10.12
Life Sciences Tools & Services Industry
- Max
- 12.46
- Q3
- 6.70
- Median
- 4.24
- Q1
- 2.68
- Min
- 0.73
RGEN’s P/S Ratio of 10.12 is in the upper echelon for the Life Sciences Tools & Services industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
AXON
23.59
Aerospace & Defense Industry
- Max
- 13.67
- Q3
- 7.92
- Median
- 4.65
- Q1
- 2.68
- Min
- 0.82
At 23.59, AXON’s P/B Ratio is at an extreme premium to the Aerospace & Defense industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
RGEN
3.39
Life Sciences Tools & Services Industry
- Max
- 7.99
- Q3
- 4.69
- Median
- 3.30
- Q1
- 1.88
- Min
- 1.02
RGEN’s P/B Ratio of 3.39 is within the conventional range for the Life Sciences Tools & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | AXON | RGEN |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 183.06 | -- |
| Price-to-Sales Ratio (TTM) | 24.98 | 10.12 |
| Price-to-Book Ratio (MRQ) | 23.59 | 3.39 |
| Price-to-Free Cash Flow Ratio (TTM) | 164.74 | 64.40 |